20-Jul-2012 - Synthon BV

Synthon enters into global license agreement with Amgen and Watson for biosimilar trastuzumab

Synthon announced that it has entered into a global license agreement with Amgen Inc. and Watson Pharmaceuticals, Inc. for Synthon’s trastuzumab, being developed as a biosimilar to Herceptin®, which is currently approved for treatment of breast cancer and gastric cancer. Earlier this year Synthon successfully completed a Phase I clinical trial in Europe showing bio-equivalence between its trastuzumab biosimilar and Herceptin®. The company was preparing for a confirmatory Phase III trial for Europe with this compound.

Under the agreement, Watson has acquired the license to the biosimilar program and has contributed it to the Amgen/Watson biosimilars collaboration. Amgen and Watson will assume responsibility for all future development work worldwide, including Phase III clinical trials, as well as global manufacturing and commercialization. Synthon will provide transitional support as set forth in the agreement. The deal entitles Synthon to an initial payment and potentially a milestone fee and royalties on net sales. Synthon will also receive compensation for its transitional support activities under the agreement. Synthon has retained rights to move forward independently with a HER2-targeted antibody-drug conjugate (ADC) candidate using its proprietary Linker-Drug technology.

Synthon’s trastuzumab is one of the most advanced products in the company’s biopharmaceuticals pipeline. It is one of the first trastuzumab biosimilar products to have completed a Phase I trial in Europe.

Additional details of the transaction were not disclosed.

Facts, background information, dossiers
More about Synthon
  • News

    Synthon Announces Successful Outcomes from Phase III Study of Synthon’s Glatiramer Acetate

    Synthon announces that data from the open-label extension of the Phase III GATE study of the Company’s generic glatiramer acetate in patients with relapsing remitting multiple sclerosis (RRMS) demonstrate that efficacy, safety and tolerability were maintained over the entire two-year study ... more

    Antitope and Synthon announce collaboration

    Antitope Limited, an Abzena company, announced that it will collaborate with Synthon Biopharmaceuticals BV, to assess the potential immunogenicity of candidate antibodies for Synthon’s ADC programmes. Antitope will use its EpiScreen™ technology, a highly accurate and sensitive ex vivo human ... more

    Synthon and MAB Discovery sign discovery agreement

    Synthon Biopharmaceuticals BV and MAB Discovery GmbH announced the execution of a research and license agreement. Under the terms of the agreement, MAB Discovery will generate antibodies for targets selected by Synthon in support of the company’s development of antibody-drug conjugates (ADC ... more

  • Companies

    Synthon BV

    Undertaking what others cannot or dare not. As researchers and entrepreneurs, that is clearly the path for us. In the next ten years we are determined to shape our future by extending the vertical integration of our activities, entering new markets and developing new classes of product. Sy ... more

More about Amgen
  • News

    Amgen Invests $66 Million In Oxford Nanopore Technologies

    Amgen and Oxford Nanopore Technologies Ltd. announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to ... more

    Amgen acquires Medigene spin-off Catherex

    Medigene AG announced that Amgen Inc., USA, will acquire 100% of Catherex, Inc., USA, a spin-off of Medigene. As a main shareholder of Catherex, Medigene Inc., USA, is entitled to approximately 40% of payments to be made by Amgen. The Company was informed about the execution of the correspo ... more

    UCB and Amgen Initiate Sclerostin Antibody Phase 3 program in patients with postmenopausal osteoporosis

    UCB and Amgen announced the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis."We look forward to working with UCB on the CDP7851/AMG 785 Phase 3 program," said Sean E. Harper, M.D., executive vice president ... more

  • Companies

    Amgen Research GmbH

    At Amgen, we rely on science and innovation to develop therapies that significantly improve the lives of people - and perhaps even save lives. The patient is at the center of everything we do. The Amgen values ​​guide us in implementing our business strategies and are the basis for our work ... more

    Amgen Europe B.V.

    Amgen is a leading human therapeutics company in the biotechnology industry. For 25 years, the company has tapped the power of scientific discovery and innovation to dramatically improve people’s lives. Amgen pioneered the development of novel products based on advances in recombinant DNA ... more

    AMGEN GmbH

    At Amgen, we rely on science and innovation to develop therapies that significantly improve the lives of people - and perhaps even save lives. The patient is at the center of everything we do. The Amgen values ​​guide us in implementing our business strategies and are the basis for our work ... more

  • Associations

    Amgen Foundation

    The Amgen Foundation seeks to advance science education, improve quality of care and access for patients, and support resources that create sound communities where Amgen staff members live and work. more

More about Watson Pharmaceuticals
  • News

    Watson Completes Actavis Acquisition

    Watson Pharmaceuticals, Inc. announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion.  The combination creates the world's third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion. Watson funded ... more

    Watson Names Robert A. Stewart Senior Vice President, Global Operations

    Watson Pharmaceuticals announced that Robert A. Stewart has joined the Company in the newly created position of Senior Vice President, Global Operations, effective immediately. In this position, Mr. Stewart will have responsibility for global manufacturing, supply chain, quality and technic ... more

    Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit

    Watson Pharmaceuticals, Inc. announced a license agreement with GeneraMedix, Inc. for the exclusive US marketing rights to a generic version of Ferrlecit (sodium ferric gluconate complex in sucrose injection), a drug indicated for the treatment of iron deficiency anemia in hemodialysis pati ... more

  • Companies

    Watson Pharmaceuticals, Inc.

    Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical). more